Growth factor delivery system with nanoscaffold materials repairs canine mandibular defects

doi:10.3969/j.issn.2095-4344.2013.21.003

Abstract

Abstract:

BACKGROUND: Scaffold materials are combined with cytokines to construct tissue-engineered bone, which cannot be limited by vascularization and cell culture. This reconstruction mode is able to induce a large-scale practical tissue-engineered bone.
OBJECTIVE: To observe the ability of chitosan microsphere/nano-hydroxyapatite/poly(lactic-co-glycolic acid) scaffold with slow-released growth factors to repair critical mandibular defects in a dog.
METHODS: Animal models of bilateral critical mandibular bone defects were established in 12 hybrid dogs. One side was implanted a chitosan microsphere/nano-hydroxyapatite/poly(lactic-co-glycolic acid) scaffold with bone morphogenetic protein 2, transforming growth factor-β1 and vascular endothelial growth factor 165 (experimental group); and the other side was implanted a chitosan microsphere/nano-hydroxyapatite/poly(lactic-co-glycolic acid). Manbidular specimens were harvested at postoperative weeks 4, 8 and 12 to carry out X-ray, histological and immunohistochemical examinations.
RESULTS AND CONCLUSION: After surgery, the X-ray gray value and osteocalcin integral absorbance value in the experimental group were higher than those in the control group at different time points (P < 0.05), showing that the osteogenic ability of the compound growth factor scaffold is superior to the scaffold without growth factor in the repair of bone defects. Histological observation results showed that the ossification time and effect in the experimental group were better than those in the control group at different time point after surgery, indicating that the chitosan microsphere/nano-hydroxyapatite/poly(lactic-co-glycolic acid) scaffold with bone morphogenetic protein 2, transforming growth factor-β1 and vascular endothelial growth factor 165 can be faster and more effective to promote bone defect repair.

Key words: biomaterials, tissue-engineered bone materials, growth factor, bone morphogenetic protein 2, chitosan, hydroxyapatite, poly(lactic-co-glycolic acid), bone scaffold materials, mandibular bone defects, ossification, osteocalcin, other grants-supported paper

CLC Number:

R318

Zhou Qing-mei, Sun Jian, Li Ya-li, Chen Li-qiang, Xu Yao-xiang. Growth factor delivery system with nanoscaffold materials repairs canine mandibular defects [J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.21.003.

Figures/Tables 4

References

[1] Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniomandibulocacial nonunions. Clin Orthop Relat Res.1986;(205):299-308.

[2] Hollinger JO,Kleinschnidt JC. The critical size defect as an experimental model to test bone repair materials. J craniofac Surg.1990;1(1):60-68.

[3] Ma J,Zhao YM,Zheng H,et al.Kouqiang Hemian Xiufuxue Zazhi.2008; 9(3):165-168.马佳,赵铱民,郑红,等. 经Ⅱ型胶原修饰的快速成形聚酯材料对软骨细胞黏附和增殖的影响[J].口腔颌面修复学杂志,2008,9(3): 165-168.

[4] Xu YX,Li YL,Chen LQ,et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu.2010;14(3):452-456.许尧祥,李亚莉,陈立强,等.壳聚糖微球/纳米羟基磷灰石/聚乳酸-羟基乙酸复合支架制备及其蛋白缓释效果:与单纯纳米羟基磷灰石/聚乳酸-羟基乙酸支架、壳聚糖微球的比较[J].中国组织工程研究与临床康复,2010,14(3):452-456.

[5] An SC,Sun J,Li YL,et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(25):4615-4618.安世昌,孙健,李亚莉,等. 复合壳聚糖纳米微球聚乳酸-羟基乙酸/纳米羟基磷灰石缓释载体系统对蛋白的缓释作用[J].中国组织工程研究与临床康复,2011,15(25):4615-4618.

[6] Liu Y,Ye MC.Kouqiang Hemian Waike Zazhi. 2010;6(3): 215-218.刘扬,叶茂昌.骨组织工程支架材料的机械强度及其制备[J].口腔颌面外科杂志,2010,6(3):215-218.

[7] The Ministry of Science and Technology of the People’s Republic of China. Guidance suggestion of caring laboratory animals.2006-09-30.中华人民共和国科学技术部.关于善待实验动物的指导性意见. 2006-09-30.

[8] Wang AH,Chen XG,Liu CS,et al.Preparation and characteristics of chitosan microspheres in different acetylation as drug carrier system.J Microencapsul.2008; 26(7):593-602.

[9] Chen W,Liu ZQ,Yue YH,et al.Zhongguo Xiufu Chongjian Waike Zazhi. 2012;8(8):989-992.陈伟,刘仲前,岳远辉,等.bFGF壳聚糖微球的制备及检测[J].中国修复重建外科杂志,2012,8(8):989-992.

[10] Wang QZ,Chen XG,Li ZX,et al.Preparation and blood coagulation evaluation of chitosan microspheres.J Mater Sci Mater Med.2008;19(3):1371-1377.

[11] Grenha A,Remunan-Lopez C,Carvalho EL,et al.Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins.Eur J Pharm Biopharm.2008;69(1):83-93.

[12] Li B,He HW,Liao XL,et al.Shengwu Yixue Gongchengxue Zazhi. 2011;10(5):1035-1039.李波,何华伟,廖晓玲,等.纳米骨组织工程支架材料生物学效应研究进展[J].生物医学工程学杂志,2011,10(5):1035-1039.

[13] Guo X,Gough JE,Xiao P,et al.Fabrication of nanostructured hydroxyapatite and analysis of human osteoblastic cellular response. J Biomed Mater Res A. 2007;82(4):1022-1032.

[14] Liu ZS,Hou YD.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(42):7911-7914.刘顺振,侯玉东.骨组织工程支架材料的研究进展及临床应用[J].中国组织工程研究与临床康复,2011,15(42):7911-7914.

[15] Jiang W,Hu ZM,Hao J,et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(41):7751-7754.江维,胡侦明,郝杰,等.骨形态发生蛋白9的成骨效应研究与进展[J].中国组织工程研究与临床康复,2011,15(41):7751-7754.

[16] Wang HH,Sun CY,Shi TF,et al.Preparation,fundamental characteristics and biosafety evalution of compound rhBMP-2 /CPC. Wuhan Uni Tech Mat Sci Ed.2006; 21(1): 116.

[17] Zhao JL,He LS,Liu BL,et al. Kouqiang Hemian Waike Zazhi. 2003;13(3):193-195.赵晋龙,何黎升,刘宝林,等.钛种植体与单纯珊瑚及复合BMP珊瑚代用品结合的实验研究[J].口腔颌面外科杂志,2003,13(3): 193-195.

[18] Mara CS,Sartori AR,Duarte AS,et al.Periosteum as a source of mesenchymal stem cells:the effects of TGF-beta3 on chondrogenesis.Clinics(Sao Paulo).2011;66(3):487-857.

[19] Olivos-Meza A,Fitzsimmons JS,Casper ME,et al. Pretreatment of periosteum with TGF-beta1 in situ enhances the quality of osteochondral tissue regenerated from transplanted periosteal grafts in adult rabbits. Osteoarthritis Cartilage,2010;18(9):1183-1191.

[20] Zhang XH,Yu ZH,Zhang GY,et al.Kouqiang Yixue Yanjiu. 2010;4(2):171-174.张小恒,余占海,张国英,等.转化生长因子-β1对大鼠牙周组织中白细胞介素-6、骨钙素水平的影响[J].口腔医学研究,2010, 4(2): 171-174.

[21] Warren SM,Greenwald JA,Spector JA,et al.New developments in cranial suture research.Plast Reconstr Surg.2001;107(2):523-540.

[22] Akech J,Wixted JJ,Bedard K,et al.Runx2 association with progression of prostate cancer in patients:mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.Oncogene.2010;29(6):811-821.

[23] Shen J.Dangdai Yixue. 2012;8(24):24-26.沈颉.血管内皮生长因子(VEGF)在血管外膜成纤维细胞的表达研究[J].当代医学,2012,8(24):24-26.

[24] Li DS,Cai B,Liu JG,et al.Zhonghua Guanjie Waike Zazhi. 2012;8(4):574-580.李冬松,蔡波,刘建国,等.血管内皮生长因子对脂肪干细胞成骨分化基因转录水平的调节[J].中华关节外科杂志,2012,8(4): 574-580.

[25] He SJ,Zheng H,Ni WD. Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(20):3611-3615.何盛江,郑华,倪卫东.重组人血管内皮生长因子165/重组人骨形态发生蛋白2/脱蛋白骨与深低温冷冻骨成骨能力的比较[J].中国组织工程研究,2012,16(20):3611-3615.

[26] Xu Y,Wang F.Wuhan Shangye Fuwu Xueyuan Xuebao. 2011; 12(6):88-90.徐勇,王峰.骨钙素的研究进展及其与运动的联系[J]. 武汉商业服务学院学报,2011,12(6):88-90.

[27] Chang X,Hou ZM,Caitian GM,et al.Huaxi Kouqiang Yixue Zazhi. 2005;23(5):424-426.常新,侯志明,柴田恭明,等.碱性磷酸酶和骨钙素在成骨过程中表达的定量研究[J].华西口腔医学杂志,2005,23(5):424-426.